Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

Launched by XUANWU HOSPITAL, BEIJING · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of brain scan called PET/MR imaging to help diagnose and treat serious brain conditions like Alzheimer's disease, Parkinson's disease, epilepsy, and malignant brain tumors. The researchers want to find out if this new imaging technology can help doctors make earlier and more accurate diagnoses, which is really important for effective treatment. By participating in this trial, individuals will have a PET/MR scan of their brain to see how well this technology works for these conditions.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have been diagnosed with mild cognitive impairment, Alzheimer's disease, rapid eye movement sleep behavior disorder, Parkinson's disease, epilepsy, or malignant brain tumors. They should also be currently receiving treatment in the hospital. However, those who have had certain treatments in the past few weeks or have specific medical issues that may affect the scan cannot participate. If you or a loved one is considering joining this trial, you can expect a thorough examination involving the PET/MR scan, which can provide valuable information for future brain disease treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines.
• • 2. Patients admitted to our hospital for inpatient treatment.
• Exclusion Criteria:
• • 1. Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month.
• • 2. Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination.
• • 3. patients with poorly controlled blood sugar and ineffective medication intervention.
• • 4. Patients with absolute contraindications for PET/MR examination.
• • 5. Karnofsky Performance Score (KPS) \<60.